Drug Trial Radar · NCT07741045
Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 5, 2026
Primary completion
Jan 15, 2028
Study completion Nov 15, 2028
Sponsor
- Lead sponsor
- Hangzhou PhecdaMed Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients. This study plans to enroll approximately 300 EOPD participants, who will be randomized in a 1:1 ratio to two cohorts (Cohort 1: 200 mg dose group; Cohort 2: 400 mg dose group). Within each cohort, successfully screened participants will be stratified by stable use of dopamine receptor agonists (Yes vs. No) and stable use of Monoamine Oxidase B (MAO-B) inhibitors (Yes vs. No), and within each stratum, randomized in a 2:1 ratio to the TJ0113 Capsules group and the placebo group, with approximately 100 assigned to the TJ0113 Capsules group and approximately 50 assigned to the placebo group. In this trial, the sample size for the TJ0113 Capsules 200 mg group, TJ0113 Capsules 400 mg group, and placebo group will each be approximately 100 participants. After randomization, during the double-blind treatment period, participants will receive continuous oral administration of TJ0113 Capsules or placebo for 26 weeks. After the double-blind treatment ends, participants will enter the open-label treatment period. During the open-label treatment period, all participants will receive oral TJ0113 Capsules for 26 weeks, and the dose of TJ0113 Capsules will be consistent with the dose of the investigational product taken by the participant during the double-blind treatment period (regardless of whether they took TJ0113 Capsules or placebo during the double-blind treatment period). After the open-label treatment period ends, participants will continue to receive a safety follow-up for 1 week (telephone follow-up). From the screening period to the end of the double-blind treatment period, all participants must maintain their original background anti-PD medication regimen unchanged; from the open-label treatment period to the end of the study, changes to the dose of stably received anti-PD medications are discouraged, but if necessary, the dose may be adjusted at the discretion of the investigator.
Conditions
- Parkinson's Disease (PD)
- Parkinson Disease 6, Early-Onset
Interventions
TJ0113 200mgDrug
100 mg Capsule, 2 Capsules Once Daily
TJ0113 400mgDrug
100 mg Capsule, 4 Capsules Once Daily
PlaceboDrug
2 Capsules or 4 Capsules, Once Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score in off-anti-PD medication state at Week 26. "Off-anti-PD medication state" is defined as: ≥12 hours after the last dose of anti-PD medicationTime frame: After 26 weeks of treatment
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Not yet recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
The Third Xiangya Hospital, Central South University
Changsha, Hunan, China · Not yet recruiting
Xiangya Hospital, Central South University
Changsha, Hunan, China · Not yet recruiting
General Hospital of Nuclear Industry (The Second Affiliated Hospital of Soochow University)
Suzhou, Jiangsu, China · Not yet recruiting
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang, China · Not yet recruiting
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Huzhou Central Hospital
Huzhou, Zhejiang, China · Recruiting
Jiaxing Second Hospital
Jiaxing, Zhejiang, China · Recruiting
Lishui Municipal People's Hospital
Lishui, Zhejiang, China · Not yet recruiting
Taizhou Central Hospital
Taizhou, Zhejiang, China · Not yet recruiting
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China · Recruiting
Wenzhou Central Hospital
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.